What is VarmX?
VarmX is a biotechnology company dedicated to developing innovative therapies aimed at restoring blood coagulation in patients. Its primary focus is on leveraging Factor Xa direct oral anticoagulants to address severe bleeding conditions and mitigate surgical bleeding risks. The company's lead program centers on a universal bypassing agent designed for rapid hemostatic control, positioning VarmX at the forefront of therapeutic advancements in hematology and critical care medicine. This strategic financing round indicates a strong market validation for its scientific approach and therapeutic pipeline.
How much funding has VarmX raised?
VarmX has raised a total of $77.2M across 2 funding rounds:
Series A
$9M
Series B
$68.2M
Series A (2018): $9M with participation from BGV (BioGeneration Ventures, Uniiq, Leiden University, and InnovationQuarter
Series B (2023): $68.2M led by Ysios Capital, Sound Bioventures, Lundbeckfonden Ventures, Life Sciences Partners, The European Innovation Council, INKEF Capital B.V, BGV (BioGeneration Ventures, and InnovationQuarter
Key Investors in VarmX
BGV (BioGeneration Ventures
BioGeneration Ventures is a venture capital firm specializing in seed investments for innovative early-stage life science companies, particularly in Europe. They act as lead investors and offer expertise and support to accelerate product development for companies addressing high unmet medical needs in the biotech sector.
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide. The firm provides biotech ventures with the necessary resources to develop novel therapies aimed at addressing significant unmet medical needs.
Lundbeckfonden Ventures
Lundbeckfonden Ventures is an investment arm of the Lundbeck Foundation, focusing on venture capital investments in promising life science companies. They support the development of innovative therapies and technologies within the biomedical field.
What's next for VarmX?
The substantial capital infusion, particularly the recent major strategic investment, signals VarmX's transition into a scaling phase. This funding is expected to accelerate the clinical development of its lead program, potentially enabling broader patient access and further research into its applications. The company is likely to expand its research and development capabilities, bolster its regulatory affairs team, and potentially initiate new clinical trials to explore additional indications for its innovative coagulation therapies. This strategic backing from prominent investors suggests confidence in VarmX's ability to navigate the complex drug development pathway and achieve significant milestones in the biotechnology sector.
See full VarmX company page
